Electra Therapeutics, Inc. Common stock (ETRA) - Total Assets
Based on the latest financial reports, Electra Therapeutics, Inc. Common stock (ETRA) holds total assets worth $106.50 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ETRA cash flow metrics for how efficiently the company converts equity into cash flow.
Electra Therapeutics, Inc. Common stock - Total Assets Trend (2024–2025)
This chart illustrates how Electra Therapeutics, Inc. Common stock's total assets have evolved over time, based on quarterly financial data. See latest Electra Therapeutics, Inc. Common stock stock price today for real-time trading data and today's change.
Electra Therapeutics, Inc. Common stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Electra Therapeutics, Inc. Common stock's total assets of $106.50 Million consist of 96.1% current assets and 3.9% non-current assets. Explore ETRA working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Electra Therapeutics, Inc. Common stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Electra Therapeutics, Inc. Common stock's current assets represent 96.1% of total assets in 2025, a decrease from 100.0% in 2024.
- Cash Position: Cash and equivalents constituted 33.2% of total assets in 2025, down from 76.1% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Electra Therapeutics, Inc. Common stock Competitors by Total Assets
Key competitors of Electra Therapeutics, Inc. Common stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥7.07 Billion |
|
Nanobiotix S.A
PA:NANO
|
France | €45.17 Million |
|
Savara Inc
NASDAQ:SVRA
|
USA | $192.14 Million |
Electra Therapeutics, Inc. Common stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.37 | 9.82 | - |
| Quick Ratio | 7.37 | 9.82 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | $86.73 Million | $85.76 Million | - |
Electra Therapeutics, Inc. Common stock - Advanced Valuation Insights
This section examines the relationship between Electra Therapeutics, Inc. Common stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 5.71 |
| Asset Growth Rate (YoY) | 411.7% |
| Total Assets | $99.37 Million |
| Market Capitalization | $567.41 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Electra Therapeutics, Inc. Common stock's assets at a significant premium (5.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Electra Therapeutics, Inc. Common stock's assets grew by 411.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Electra Therapeutics, Inc. Common stock (2024–2025)
The table below shows the annual total assets of Electra Therapeutics, Inc. Common stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $99.37 Million | +411.68% |
| 2024-12-31 | $19.42 Million | -- |
About Electra Therapeutics, Inc. Common stock
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professio… Read more